Endocrine Abstracts

Objective: The objective of this clinical trial is to compare four strategies of management of postoperative radioiodine ablation in a 2×2 factorial design, each strategy combining a method of TSH stimulation and an activity of 131I. The primary endpoint is the rate of thyroid ablation.Patients and methods: This multicentric, randomized, controlled, phase III trial involved 24 French centers, and compared 4 strategies for postoperative radioiodine a...

Introduction: Adrenocortical carcinoma (ACC) is a rare tumor of the adrenals with poor prognosis (survival rate for metastatic patients <15% at 5 years). Mitotane (o,p′-DDD) is the main therapeutic option with up to 66% objective response rates in patients with serum levels between 14 and 20 mg/l. Its two main metabolites are o,p′-DDA and o,p′-DDE which plasma levels are not correlated to therapeutic response. Mitotane is a lipophilic drug that accumulate...

Malignant pheochromocytoma and paraganglioma (PPGLs) are rare diseases with a heterogeneous behaviour. 131I-MIBG therapy and the cyclophosphamide-dacarbazine-vincristine chemotherapy regimen (CVD) constitute the most popular options in the metastatic setting. We have investigated the antitumor effect of temozolomide (TMZ), in patients with metastatic PPGLs. Efficacy was primary endpoint, safety and identification for prognosis factors of response were secondary endpoints.<...

Context: An increased mortality by cancer is reported in grafted patients.Objective: This multicentric study aimed to investigate whether the prognosis of thyroid cancer was modified by transplantationResults: Sixty nine patients (35 M/34 F; median age 41 years) with a history of both thyroid cancer and transplantation were recruited via specialized networks (TUTHYREF and DIVAT). Evolution and outcome were retrospectively analyzed ...

Pheochromocytoma and paraganglioma are defined as malignant by the occurence of metastasis in extra paraganglionic sites. The natural evolution of these tumors remains unknown.The aim of our retrospective study was to define the progression-free survival (PFS) of untreated Malignant Pheochromocytoma and Paraganglioma (MPP) at 12 months (12 m-PFS) and to look for prognostic markers of 12 m-PFS. We analyzed clinical parameters of patients followed within 8...